CVS expects elevated medical costs to continue to pressure its performance this year, “and as a result we are not providing a formal outlook at this time.”
Related Posts
Nvidia turned CoreWeave into a major player in AI years before helping to save its IPO
CoreWeave has found a big market in selling Nvidia’s popular AI processors, but the company has a challenging story to sell to public investors.
Citi revamped its list of highest conviction stocks going into 2025. These names made the grade
As the new year approaches, investors should keep an eye on some stocks that could outperform over the next 12 months, according to Citi.
El-Erian says U.S. recession risks are now ‘uncomfortably high’
“If the U.S. slows down, the rest of the world will slow down more,” the veteran economist warned.